Bio Path reported $677K in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Baxter International USD 19.41B 377M Sep/2026
Bio Path USD 677K 13K Mar/2026
Cipla INR 434.34B 9.38B Sep/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 138.36M 7.5M Jun/2026
CSL USD 37.9B 1.5B Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Karyopharm Therapeutics USD 131.42M 23M Mar/2026